ANTARES PHARMA, INC.
DelistedCIK 1016169fmd_198E9QV8ZP4F563DMCD7MRCRKYManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2022, 49 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 23 | 21 | 27 | 46 | 52 | 55 | 64 | 124 | 150 | 184 |
| Cost of revenue | 10 | 9 | 11 | 19 | 29 | 27 | 31 | 50 | – | – |
| Gross profit | 13 | 11 | 15 | 26 | 23 | 27 | 32 | 73 | – | – |
| Research and development | 15 | 15 | 19 | 20 | 20 | 12 | 12 | 11 | 10 | 15 |
| Selling, general and administrative | 10 | 17 | 32 | 27 | 28 | 32 | 37 | 62 | 63 | 74 |
| Total operating expenses | 25 | 32 | 50 | 47 | 48 | 44 | – | – | – | – |
| Operating income | (11) | (21) | (35) | (20) | (24) | (16) | (4) | 1 | 14 | 66 |
| Interest expense | – | – | – | – | – | 1 | 3 | 4 | 4 | 4 |
| Other non-operating income (expense) | 0 | 0 | (0) | (0) | (0) | (1) | (2) | (3) | (4) | (4) |
| Income before taxes | (11) | (21) | (35) | (20) | (24) | (17) | (7) | (2) | 10 | 62 |
| Income tax expense | – | (0) | 0 | 0 | 0 | – | – | 0 | (46) | 16 |
| Net income from continuing operations | – | (21) | (35) | (21) | (24) | – | – | (2) | 56 | 46 |
| Net income | (11) | (21) | (35) | (21) | (24) | (17) | (7) | (2) | 56 | 46 |